Исследование эффективности и безопасности DFL24498 в лечении АКК
A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Participants With Atopic Keratoconjunctivitis (AKC)
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. The study consists of 2 cohorts: the adult cohort includes approximately 138 participants and the pediatric cohort which includes approximately 15 participants. The cohorts will be randomized separately. Adult participants will be randomized in a 1:1 ratio, while pediatric participants will be randomized in a 2:1 ratio to receive DFL24498 or vehicle.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
The study will consist of 3 periods:
- Washout period (from Day -7 ± 1 to Day 1),
- Treatment Period (from randomization through Week12) and
- Follow-up period (Weeks 13 to 16).
Тип исследования
Тип исследования
Регистрация (Оцененный)
Регистрация
Фаза
Фаза
- Фаза 3
Контакты и местонахождение
Контакты исследования
Контакты исследования
- Имя: Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI)
- Номер телефона: +39 02 583 831
Места учебы
-
-
-
Córdoba, Испания, 14012
- Рекрутинг
- METAVISION ARRUZAFA S.L. (Hospital Arruzafa)
-
Santiago de Compostela, Испания, 15706
- Рекрутинг
- Miranza Galicia
-
Valencia, Испания, 46015
- Рекрутинг
- Fundación de Oftalmología Médica de la Comunitat Valenciana (FOM)
-
Valladolid, Испания, 47011
- Рекрутинг
- OBA - Universidad de Valladolid
-
Zaragoza, Испания, 50009
- Рекрутинг
- Hospital Universitario Miguel Servet
-
-
-
-
-
Bologna, Италия, 40138
- Рекрутинг
- IRCCS AOU di Bologna - Policlinico Sant'Orsola UO Oftalmologia
-
Chieti, Италия, 66100
- Рекрутинг
- Ospedale SS Annunziata, ASL 2 Lanciano Vasto Chieti
-
Florence, Италия, 50134
- Рекрутинг
- Azienda Ospedaliero Universitaria Careggi
-
Roma, Италия, 00161
- Рекрутинг
- AOU Policlinico Umberto I
-
Roma, Италия, 00128
- Рекрутинг
- Fondazione Policlinico Universitario Campus Bio-Medico
-
Verona, Италия, 37134
- Рекрутинг
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
Florida
-
Jacksonville, Florida, Соединенные Штаты, 32256
- Рекрутинг
- Bowden Eye Associates - Southside Location
-
Miami, Florida, Соединенные Штаты, 33136
- Рекрутинг
- University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute
-
-
Georgia
-
Morrow, Georgia, Соединенные Штаты, 30260
- Рекрутинг
- Clayton Eye Clinical Research
-
-
Missouri
-
St Louis, Missouri, Соединенные Штаты, 63131
- Рекрутинг
- Ophthalmology Associates
-
-
New York
-
New York, New York, Соединенные Штаты, 10017
- Рекрутинг
- NYU Langone Health - Eye Center
-
-
North Carolina
-
Durham, North Carolina, Соединенные Штаты, 27710
- Рекрутинг
- Duke Eye Center - Ophthalmology
-
-
Tennessee
-
Memphis, Tennessee, Соединенные Штаты, 38119
- Рекрутинг
- Total Eye Care, PA
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77030
- Рекрутинг
- Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
-
Male or Female aged ≥ 10 and ≤ 65 years.
-
Diagnosis of AKC in both eyes, including the presence or medical history of the following:
- other atopic condition (ie., atopic dermatitis, periocular eczema, asthma, allergic rhinitis), AND
- chronic allergic blepharoconjunctivitis and/or keratoconjunctivitis.
-
Ocular itching of at least 50 as assessed by VAS scale.
-
Corneal fluorescein staining assessed by modified Oxford scale of at least grade 1 AND a bulbar conjunctival hyperemia assessed by VBR 10 scale of at least 40 (range 0 to 100) in the same eye.
-
A composite symptoms score (CSyS) ≥ 5 (sum of the severity scores graded 0 to 3 for each of the following: itching, tearing, ocular discomfort, photophobia, and mucous discharge score) (CSyS range of 0 to 15).
-
If a woman of childbearing potential (WOCBP), must have a negative pregnancy test at both screening and baseline visit, and use an acceptable contraception method.
Exclusion Criteria:
Participants will be excluded if any of the following criteria apply:
- Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments.
- Evidence of an active ocular infection in either eye.
- Intraocular inflammation defined as anterior chamber flare > 0 by Standardization of Uveitis Nomenclature (SUN) grading, in either eye.
- Known or suspected ocular malignancy (ocular surface, intraocular, ocular adnexa).
- Presence of cancer or any other systemic or unstable disease that may affect the ability to participate in the clinical study in the opinion of the investigator including basal cell carcinoma.
- Participants that are anatomically monocular.
- Systemic disease not stabilized within 1 month before the screening visit (eg, diabetes with glycemia out of range, thyroid malfunction) or judged by the investigator to be incompatible with the study (eg, current systemic infections) or with a condition incompatible with the frequent assessment required by the study.
Note: Additional protocol defined Inclusion/Exclusion criteria apply
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: DFL24498
Participants will be administered with DFL24498 eye drops in both eyes. |
DFL24498 will be instilled in each eye for 12 Weeks. Rescue medication may be administered as required at the Investigator discretion. |
|
Плацебо Компаратор: Vehicle
Participants will be administered with vehicle eye drops in both eyes. |
Rescue medication may be administered as required at the Investigator discretion. Vehicle eye drops without active drug will be instilled in each eye for 12 Weeks. |
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change from baseline at week 6 in ocular itching score assessed by visual analog scale (VAS).
Временное ограничение: Baseline and at Week 6
|
The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point. |
Baseline and at Week 6
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change from baseline at week 6 in corneal epithelial fluorescein staining, scored by modified Oxford scale, in the study eye.
Временное ограничение: Baseline and at Week 6
|
Fluorescein will be applied to the inferior fornix of the palpebral conjunctiva of each eye. To avoid the phenomenon of quenching, staining will be assessed within 1 to 4 minutes from fluorescein instillation. Examination will be performed at the slit-lamp using blue (cobalt) light. Corneal fluorescein staining will be graded according to the modified Oxford scale (7-point scale: 0, 0.5. 1, 2, 3, 4, 5). |
Baseline and at Week 6
|
|
Change from baseline at week 6 in bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100), in the study eye.
Временное ограничение: Baseline and at Week 6
|
Bulbar conjunctival redness will be assessed at the slit-lamp examination using white light prior to vital dye instillation and graded according to the VBR 10 scale. |
Baseline and at Week 6
|
|
Change from baseline over time in ocular itching score assessed by VAS.
Временное ограничение: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
The ocular itching VAS ranges from 0 to 100 mm (0 mm = no ocular itching at all, 100 mm = intolerable itching). Participants will be asked to subjectively rate the current severity of ocular itching at each time point. |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline over time in ocular symptoms of itching, tearing, discomfort, mucous discharge, and photophobia on a 4-point scale (0 to 3).
Временное ограничение: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
Ocular symptoms are assessed using a 4-point severity scale ranging from 0 (none) to 3 (severe). Five ocular symptoms, itching, tearing, ocular discomfort (including burning, stinging, and foreign body sensation), mucous discharge, and photophobia are evaluated in the study eye. A composite symptom score is described in calculated at screening and Baseline by summing the individual symptom scores, resulting in a total score range of 0 to 15, with higher scores indicating greater symptom severity. |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline over time in corneal fluorescein staining (modified Oxford scale) in the study eye.
Временное ограничение: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
Corneal fluorescein staining modified Oxford scale (0-5) as per corneal dot count in each eye. |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline over time in bulbar conjunctival hyperemia assessed by VBR 10 scale (0 to 100) in the study eye.
Временное ограничение: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
Bulbar conjunctival hyperemia assessed by Validated Bulbar Redness (VBR) 10 scale (0 to 100). |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline over time in signs of tarsal papillary reaction, corneal neovascularization, cicatrizing conjunctivitis and blepharitis on a 4-point scale (0 to 3) in the study eye.
Временное ограничение: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
Change in signs on a 4-point scale (0 to 3) in the study eye. |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline at week 6 and 12 in the QoL scores assessed by the Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ-S) (assessed in the adult cohort only)
Временное ограничение: Baseline and at Week 6 and Week 12.
|
Standardized Rhinoconjunctivitis QoL Questionnaire (RQLQ[S]) is a validated questionnaire that assesses QoL specifically in patients with rhinoconjunctivitis. There are 28 questions, which are categorized under 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Each question is scored on a 7-point scale from no impairment (score 0) to severe impairment (score 6). |
Baseline and at Week 6 and Week 12.
|
|
Patient Global Impression of Change (PGIC) at week 6 and week 12 (assessed in the adult cohort only)
Временное ограничение: At week 6 and week 12.
|
PGIC is a short questionnaire used to assess how a participant perceives changes in their condition following treatment, on a scale ranging from 1 to 7. |
At week 6 and week 12.
|
|
Number of Participants receiving rescue medication over time after week 6
Временное ограничение: Week 6 to Week 12
|
Participants who received rescued medication over time after week 6 (visit 4). |
Week 6 to Week 12
|
|
Number of participants with treatment-emergent adverse events and serious adverse events (SAEs)
Временное ограничение: Up to Week 16
|
Any adverse events occurring or worsening after the first administration of investigational product is classified as "treatment-emergent" adverse events and does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important. |
Up to Week 16
|
|
Change from baseline over time in best corrected distance visual acuity (BCDVA) in each eye.
Временное ограничение: Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
Best corrected visual acuity (BCDVA) is determined by careful refraction according to the standard protocol for refraction. BCDVA is measured by Early Treatment of Diabetic Retinopathy Study chart. |
Baseline and at Week 4, Week 6, Week 8, Week 12, and Week 16
|
|
Change from baseline at week 12 in corneal endothelial cell density in each eye (only at selected sites that have the required equipment).
Временное ограничение: Baseline and at week 12
|
Corneal central region endothelial cell density will be determined for each eye using specular microscopy and expressed as the number of cells/mm2 using the Cell Density readout provided by the software. |
Baseline and at week 12
|
|
Change from baseline at week 12 in dilated fundus exam in each eye
Временное ограничение: Baseline and at week 12
|
After specular microscopy, mydriatic drops will be instilled in both eyes and once adequate dilation is achieved, a fundal exam shall be performed to examine the vitreous, retina, and optic nerve. |
Baseline and at week 12
|
|
Change from baseline over time in intraocular pressure in each eye.
Временное ограничение: Baseline and at Week 6 and Week 12
|
IOP will be assessed by tonometry for each eye and will be measured in mmHg. |
Baseline and at Week 6 and Week 12
|
|
Number of participants discontinued due to tolerability during the treatment period
Временное ограничение: Baseline to week 12
|
Treatment discontinuation rate due to tolerability. |
Baseline to week 12
|
Соавторы и исследователи
Спонсор
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Оцененный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Организация пневмонии
- Заболевания иммунной системы
- Заболевания дыхательных путей
- Легочные заболевания
- Бронхиальные заболевания
- Заболевания легких, обструктивные
- Облитерирующий бронхиолит
- Бронхиолит
- Бронхит
- Трансплантат против болезни хозяина
- Синдром облитерирующего бронхиолита
- Фармацевтические решения
- Фармацевтические препараты
- Фармакологические действия
- Химические действия и используют
- Терапевтическое использование
- Решения
- Специальное использование химических веществ
- Офтальмологические решения
- Дексаметазон 21-фосфат
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- ICY-AKC-301
- 2025-522291-83-00 (Ктис)
- 2025 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .